Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. Analyst Wedbush lowered the price target from $71 to $55, reflecting concerns about the drug's development. The company focuses on treatments for neurological and psychiatric disorders, and this setback raises uncertainty about its lead drug's future progress.
Xenon Pharmaceuticals saw a 27.6% stock price plunge amid trial pauses. For readers following health-sector stocks, here is Pluang's market snapshot as of Sep 18, 2026 20:41 WIB: out of 92 priced US health stocks, 35 rose and 55 fell. Notable movers include HIMS at USD 28.40 with a 1-day change of +1.83% and 100% buy order activity, ILMN at USD 240.83 down 1.78% with 0% sell orders, and INO at USD 1.23 up 1.65% with 84% buy orders and a typical hold time of 42 days.
Duke Energy Corporation's stock is projected to rise about 8.26% to a price target of $127, down slightly from $133, reflecting confidence despite a recent price dip. The company expects a 4.42% increase in earnings per share to $1.89 and a 3.86% ris...
Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...
Paychex, a provider of human capital management solutions, will release its Q1 fiscal 2027 earnings on September 23, 2026. Analysts expect earnings per share (EPS) of $1.32, up from $1.22 last year, and revenue of about $1.63 billion, higher than las...
Barclays lowered its price target for Lennar Corporation to $70 from a higher level, citing a 52% drop in Q3 net earnings to $284 million and an 8.6% revenue decline to $8.05 billion. The homebuilder faces headwinds from rising mortgage rates and wea...
Guggenheim has raised its price target for Restaurant Brands International (QSR) to $86 from $85 and reiterated a Buy rating, reflecting confidence in the company's strategic growth. Restaurant Brands International is enhancing shareholder value thro...
